公开(公告)号：US11760987B2

公开(公告)日：2023-09-19

申请号：US16124482

申请日：2018-09-07

申请人： The Regents of the University of California ,  The United States of America as Represented by The Department of Veterans Affairs

发明人： H. Kirk Hammond ,  Mei Hua Gao ,  Ngai Chin Lai

IPC分类号： C12N9/88 ,  A61P9/04 ,  A61K48/00 ,  A01K67/027 ,  C12N15/86 ,  C12N5/10 ,  C12N15/85

CPC分类号： C12N9/88 ,  A01K67/0275 ,  A61K48/00 ,  A61P9/04 ,  C12N5/10 ,  C12N15/85 ,  C12N15/86 ,  C12Y406/01001 ,  A01K2227/105 ,  C07K2319/00

摘要： In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for treating a heart failure in a subject in need thereof comprising administering to the subject an isolated or recombinant nucleic acid, an isolated or recombinant or chimeric polypeptide, or an engineered cell, as provided herein, thereby treating the subject. In alternative embodiments, the administration reduces left ventricular (LV) hypertrophy, increases LV peak pressure development, reduced cAMP production and/or improves LV peak pressure decay in a pressure-overload in the subject. In alternative embodiments, provided are compositions and methods for: treating, ameliorating, or slowing the progress of, or protecting (preventing) an individual or a patient against heart failure; or, reducing LV hypertrophy, increasing LV peak pressure development, and/or improving LV peak pressure decay in a pressure-overload in an individual in need thereof.

公开(公告)号：US11760979B2

公开(公告)日：2023-09-19

申请号：US16784230

申请日：2020-02-06

申请人： LICENSE BIOTECHNOLOGY Co., Ltd.

发明人： Wen-Cheng Huang ,  Szu-Meng Wu

IPC分类号： C12N5/095 ,  A61K31/44 ,  A01K67/027

CPC分类号： C12N5/0695 ,  A01K67/0278 ,  A61K31/44 ,  A01K2207/15 ,  A01K2227/105 ,  A01K2267/0393

摘要： An isolated rat liver cancer stem cell line which is named as TW-1 is provided. A method for drug screening by using the isolated rat liver cancer stem cell line is also provided.

公开(公告)号：US20230277692A1

公开(公告)日：2023-09-07

申请号：US18089267

申请日：2022-12-27

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Vera Voronina ,  Corey Momont ,  John McWhirter ,  Naxin Tu ,  Lynn MacDonald ,  Andrew J. Murphy

IPC分类号： A61K49/00 ,  A01K67/027

CPC分类号： A61K49/0008 ,  A01K67/0278 ,  A01K2267/03 ,  A01K2227/105 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2217/15

摘要： Provided herein are methods and compositions related to the in vivo testing of therapeutic agents comprising a human Fc in genetically modified rodents (e.g., the testing of the pharmacokinetic and/or pharmacodynamic properties of such a therapeutic agent in genetically modified rodents). In some embodiments the genetically modified rodents express antibodies comprising a human Fc (e.g., a human IgG1 Fc, a human IgG4 Fc). In some embodiments, the rodents express fully human antibodies (i.e., antibodies having human heavy chains and human light (γ or κ) chains). In certain embodiments the genetically modified rodents comprise one or more Fc receptors with a human extracellular domain (e.g., a Neonatal Fc Receptor (FcRn), a β-2-microglobulin polypeptide (β2M), a Fc ε receptor 1 α (FcεR1α), a Fc γ receptor 1 alpha (FcγR1a), a Fc gamma receptor 2a (FcγR2a), a Fc gamma receptor 2b (FcγR2b), a Fc gamma receptor 3a (FcγR3a), a Fc gamma receptor 3b (FcγR3b), a Fc gamma receptor 2c (FcγR2c)). The transmembrane and cytoplasmic domain of such receptors can be human or non-human (e.g., rodent).

公开(公告)号：US20230272397A1

公开(公告)日：2023-08-31

申请号：US18192492

申请日：2023-03-29

申请人： Genus PLC

发明人： Andrew Mark Cigan ,  Jonathan Edward Lightner ,  Matthew Scott Culbertson ,  William Thomas Christianson ,  Benjamin Beaton ,  Brian Burger ,  Dylan Barnes ,  Matthew Campbell

IPC分类号： C12N15/113 ,  A01K67/027 ,  C12N9/22 ,  C12N15/877

CPC分类号： C12N15/113 ,  A01K67/0275 ,  C12N9/22 ,  C12N15/8778 ,  C12N2310/20 ,  A01K2217/052 ,  A01K2227/108 ,  C12N2320/34

摘要： The present disclosure relates methods and compositions useful for prevention of porcine reproductive and respiratory syndrome virus (PRRSv) in animals, including animals of the species Sus scrofa. The present teachings relate to swine wherein at least one allele of a CD163 gene has been inactivated, and to specific methods and nucleic acid sequences used in gene editing to inactivate the CD163 gene. Swine wherein both alleles of the CD163 gene are inactivated are resistant to porcine reproductive and respiratory syndrome virus (PRRSv). Elite lines comprising homozygous CD163 edited genes retain their superior properties

公开(公告)号：US20230270088A1

公开(公告)日：2023-08-31

申请号：US18059809

申请日：2022-11-29

申请人： Kymab Limited

发明人： Allan Bradley ,  E-Chiang Lee ,  Qi Liang ,  Wei Wang ,  Anais Legent ,  Ian Kirby

IPC分类号： A01K67/027 ,  C07K16/12 ,  C07K16/00 ,  C07K16/18 ,  C07K16/46 ,  A61K39/02 ,  A61K39/35 ,  C12N15/85

CPC分类号： A01K67/0278 ,  C07K16/1239 ,  C07K16/00 ,  C07K16/18 ,  A01K67/0275 ,  C07K16/1203 ,  C07K16/462 ,  A61K39/107 ,  A61K39/35 ,  A01K67/0276 ,  A01K67/0271 ,  C12N15/8509 ,  C07K2317/24 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2217/075 ,  C07K2317/14 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/92 ,  A01K2217/15 ,  C07K2317/21 ,  C07K2317/76 ,  A61K2039/505

摘要： The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.

公开(公告)号：US11740242B2

公开(公告)日：2023-08-29

申请号：US16629176

申请日：2018-07-16

申请人： Dana-Farber Cancer Institute, Inc.

发明人： William N. Haining ,  Robert Manguso ,  Adrienne Long

IPC分类号： G01N33/574 ,  A01K67/027 ,  C12N15/113

CPC分类号： G01N33/574 ,  A01K67/027 ,  C12N15/1138 ,  A01K2227/105 ,  A01K2267/0331 ,  G01N2333/70539

摘要： The present invention relates, in part, to methods of treating a cancer in a subject comprising administering to the subject a therapeutically effective amount of an agent that inhibits one or more biomarkers listed in Table 1 in combination with an immunotherapy.

公开(公告)号：US11738053B2

公开(公告)日：2023-08-29

申请号：US16329915

申请日：2017-09-01

申请人： THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

发明人： Senlin Li ,  Robert A Clark ,  Cang Chen ,  Yang Li

IPC分类号： A01N63/00 ,  C12N15/63 ,  C07H21/04 ,  A61K35/28 ,  A61K38/19 ,  A01K67/027 ,  C12N15/86

CPC分类号： A61K35/28 ,  A01K67/0276 ,  A61K38/193 ,  C12N15/86 ,  A01K2227/105 ,  A01K2267/0306 ,  C12N2740/16043

摘要： The invention relates to a method of treating chronic granulomatous disease through Hematopoietic stem cell (HSC) transplantation. The method comprises the steps of administering stem cell mobilization agent to human such that the target stem cell population migrates from host niches into the subject's blood. The target stem cells are removed from blood and administering the therapeutic stem cells to human and said therapeutic stem cells are engineered to express gp91phox. The steps are repeated multiple times i.e. at least four times. The mobilization agents used in the invention are granulocyte-colony stimulating factor and AMD3100. The method of HSC transplantation is effective in treatment of chronic granulomatous disease.

公开(公告)号：US11732273B2

公开(公告)日：2023-08-22

申请号：US16799398

申请日：2020-02-24

申请人： BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA ,  TOKAI UNIVERSITY EDUCATIONAL SYSTEM

发明人： Channabasavaiah Gurumurthy ,  Masato Ohtsuka ,  Masahiro Sato

IPC分类号： C12N5/00 ,  C12N15/85 ,  C12N5/071 ,  C12N9/22 ,  C12N15/113 ,  A01K67/027 ,  C12N15/90

CPC分类号： C12N15/85 ,  A01K67/0275 ,  C12N5/0608 ,  C12N5/0682 ,  C12N9/22 ,  C12N15/113 ,  C12N15/907 ,  A01K2227/105 ,  A01K2267/03 ,  C12N2310/20 ,  C12N2800/80

摘要： Disclosed are methods and compositions for in situ germline genome engineering. The disclosed methods and compositions may be utilized for germline genome engineering in a subject having a reproductive organ containing a fertilized zygote, via: (i) isolating or obtaining the reproductive organ from the subject after a time period following insemination of the subject; (ii) introducing a reagent composition into the reproductive organ, the reagent composition comprising a nuclease system and/or an exogeneous polynucleotide; and (iii) electroporating the reproductive organ.

公开(公告)号：US20230257768A1

公开(公告)日：2023-08-17

申请号：US18009187

申请日：2021-06-11

申请人： NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY

发明人： Isao OISHI ,  Kyoko YOSHII

IPC分类号： C12N15/85 ,  A01K67/027

CPC分类号： C12N15/8509 ,  A01K67/0275 ,  A01K2207/05 ,  C12N2310/20

摘要： According to the present invention, a poultry cell knocked-in at an egg white protein gene, a knock-in method, a method for producing a knocked-in poultry cell and an egg or a poultry containing the knocked-in poultry cell may be provided.

公开(公告)号：US11725038B2

公开(公告)日：2023-08-15

申请号：US16882147

申请日：2020-05-22

申请人： University of Pittsburgh—of the Commonwealth System of Higher Education

发明人： Michael Cascio ,  Joseph C. Glorioso, III ,  James R. Goss ,  David Krisky

IPC分类号： C07K14/705 ,  C12N15/86 ,  A61K48/00 ,  A01K67/027 ,  C12N7/00 ,  A61K38/00

CPC分类号： C07K14/705 ,  A01K67/0278 ,  A61K48/005 ,  C12N7/00 ,  C12N15/86 ,  A01K2217/20 ,  A01K2217/206 ,  A01K2227/105 ,  A01K2267/0356 ,  A01K2267/0393 ,  A61K38/00 ,  C12N2710/16643 ,  C12N2800/30

摘要： The invention provides a method of modulating electrophysiological activity of an excitable cell. The method involves causing exogenous expression of a glycine receptor (GlyR) protein in an excitable cell of a subject. Thereafter, the excitable cell is exposed to an allosteric modulator of the GlyR protein. Modulation of the exogenous GlyR protein (an ion channel) in response to the allosteric modulator modulates the electrophysiological activity of the excitable cell. The method can be used to control pain in a subject. The invention further provides a replication-defective HSV vector comprising an expression cassette encoding a GlyR protein, stocks and pharmaceutical compositions containing such vectors, and a transgenic animal.